MLi-2 | LRRK2 inhibitor

Available Options

Size:PriceQuantity 
5 mg$85.00
25 mg$295.00
Request Quote / Bulk / Custom Size
Product Inquiry

MLi-2 (1627091-47-7) is a potent (IC50 = 0.76 nM) inhibitor of leucine-rich repeat kinase 2 (LRRK2).1,2 It has greater than 295-fold selectivity against a panel of 300 kinases. CNS active. An important tool for the study of aberrant LRRK2 signaling in Parkinson’s disease.3-6

References/Citations:

  1. Fell et al. (2015) MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition; J. Pharmacol. Exp. Ther., 355 397
  2. Scott et al. (2017) Discovery of a 3-(4-Pyrimidinyl)Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity; J. Med. Chem., 60 2983
  3. Novello et al. (2022) In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity; Neurobiol. Dis., 162 105579
  4. Hwang et al. (2024) Pharmacological Inhibition of LRRK2 Exhibits Neuroprotective Activity in Mouse Photothrombotic Stroke Model; Exp. Neurobiol., 33 36
  5. Jaimon et al. (2025) Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s disease-linked LRRK2-mutant mice; Sci. Signal., 18 eads5761
  6. Pena et al. (2024) G2109S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage; NPJ. Parkinson’s Dis., 10 49
1627091-47-7, LRRK2 inhibitor, MLi-2, MLi-2 supplier, MLi2

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

MLi-2 (1627091-47-7) is a potent (IC50 = 0.76 nM) inhibitor of leucine-rich repeat kinase 2 (LRRK2).1,2 It has greater than 295-fold selectivity against a panel of 300 kinases. CNS active. An important tool for the study of aberrant LRRK2 signaling in Parkinson’s disease.3-6

References/Citations:

  1. Fell et al. (2015) MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition; J. Pharmacol. Exp. Ther., 355 397
  2. Scott et al. (2017) Discovery of a 3-(4-Pyrimidinyl)Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity; J. Med. Chem., 60 2983
  3. Novello et al. (2022) In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity; Neurobiol. Dis., 162 105579
  4. Hwang et al. (2024) Pharmacological Inhibition of LRRK2 Exhibits Neuroprotective Activity in Mouse Photothrombotic Stroke Model; Exp. Neurobiol., 33 36
  5. Jaimon et al. (2025) Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s disease-linked LRRK2-mutant mice; Sci. Signal., 18 eads5761
  6. Pena et al. (2024) G2109S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage; NPJ. Parkinson’s Dis., 10 49